検索ワード: rannsóknarinnar (アイスランド語 - 英語)

markmið rannsóknarinnar eru:
the objectives of the study are:

lokaskýrsla klínísku rannsóknarinnar
final clinical study report

aðalendapunktur rannsóknarinnar var heildarlifun.
the primary endpoint of the study was overall survival.

heildarniðurstöður rannsóknarinnar voru eftirfarandi:
the overall study results showed:

heildarlifun við lok pix301-rannsóknarinnar
pix 301 overall survival–end of study

við upphaf rannsóknarinnar var meðaltals hbv
at study entry, the mean hbv dna was

endurskoða ber niðurstöður rannsóknarinnar árlega.
results from the study to be reviewed annually.

niðurstöður rannsóknarinnar koma fram á töflu 3.
the results of the study are presented in table 3.

Í tilhögun rannsóknarinnar er ekki gert ráð fyrir
the design of the study does not allow for

fyrsti verkunarendapunktur rannsóknarinnar var hlutlægt svörunarhlutfall.
the primary efficacy endpoint of this study was orr.

lifun án versnunar í lok pix301-rannsóknarinnar
pix301 progression-free survival - end of study

aðalverkunarbreyta rannsóknarinnar var lengd tíma fram að versnun.
the primary efficacy parameter of the trial was the duration of progression-free survival.

tafla 3. sýnir samantekt á aðalniðurstöðum rannsóknarinnar.
a summary of the key study results is shown in table 3.

aðalendapunktur rannsóknarinnar var að allir lifðu af sjúkdóminn.
the primary endpoint of the study was overall survival.

frá upphafi til loka rannsóknarinnar var miðgildi breytingar á qtcf
from baseline to end of study the median change in qtcf for degarelix was

aðalendapunktur rannsóknarinnar var acr 20 svörunarhlutfall eftir 34 vikur.
the primary endpoint of the study was the acr 20 responder rate at week 34.

gerð og niðurstöður rannsóknarinnar koma fram í töflunni hér á eftir.
study features and results are presented in the table below.

aðalviðmið rannsóknarinnar var pfs skv. mati óháðs geislalæknis og krabbameinsskoðunar.
the primary endpoint of the study was pfs, as assessed by an independent radiologist and oncology review.

engin tilfelli verulegs blóðsykursfalls voru skráð í vildagliptinþáttum rannsóknarinnar.
no severe hypoglycaemic events were reported in the vildagliptin arms.

aðalendapunktur rannsóknarinnar var tíðni aukaverkana á hjarta í formeðferðarhluta rannsóknarinnar.
the primary endpoint of this study was cardiac safety during the neoadjuvant treatment period of the study.